Is quantitative spectral-domain superior to time-domain optical coherence tomography (OCT) in eyes with age-related macular degeneration?

Acta Ophthalmologica

Volumn 90, Issue 7, 2012, Pages 620-627

  Eriksson, Urban ^a   Alm, Albert ^a   Larsson, Eva ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

age related macular degeneration; quantitative optical coherence tomography; repeatability; reproducibility

Indexed keywords

A SCAN; ADULT; AGED; ARTICLE; B SCAN; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER PROGRAM; CONTROLLED STUDY; EXUDATIVE MACULAR DEGENERATION; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULAR THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TIME DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84868191429     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02112.x     Document Type: Article

References (48)

1. Bland JG, &, Altman DG, (1986): Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310. (Pubitemid 16134762)
2. Brown DM, &, Regillo CD, (2007): Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144: 627-637.
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, &, Schneider S,; ANCHOR Study Group (2006): Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444. (Pubitemid 44511558)
4. Carl Zeiss Meditec Inc. (2010): Users manual Cirrus HD-OCT model 4000 version 4.0.1, Dublin, CA, USA.
5. Diabetic retinopathy clinical research network (2006): Diurnal variation in retinal thickening measured by optical coherence tomography in center-involved macular edema. Arch Ophthalmol 124: 1701-1707.
6. Diabetic retinopathy clinical research network (2007): Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 114: 1520-1525.
7. Early Treatment Diabetic Retinopathy Study Research group (1985): Photocoagulation for diabetic macular edema; Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796-1806.
8. Eriksson U, &, Alm A, (2009): Repeatability in and interchangeability between the macular and the fast macular thickness protocols: a study on normal eyes with Stratus optical coherence tomography. Acta Ophthalmol Scand 87: 725-730.
9. Eriksson U, Larsson E, &, Holmström G, (2004): Optical Coherence tomography in the diagnosis of juvenile x-linked retinoschisis. Acta Ophthalmol Scand 82: 218-223. (Pubitemid 38515383)
10. Eriksson U, Holmström G, Alm A, &, Larsson E, (2009): A population-based study of macular thickness in full-term children assessed with Stratus OCT: normative data and repeatability. Acta Ophthalmol Scand 87: 741-745.
11. Frank RN, Schulz L, Abe K, &, Lezzi R, (2004): Temporal variations in diabetic macular edema measured by optical coherence tomography. Ophthalmology 111: 211-217. (Pubitemid 38183216)
12. Fung AE, Lalwani GA, Rosenfeld PJ, et al., (2007): An optical coherence tomography-guided, variable dosing regimen with Intravitreal Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
13. Gaudric A, Haouchine B, Massin P, Paques M, Blain P, &, Erginay A, (1999): Macular hole formation: new data provided by optical coherence tomography. Arch Ophthalmol 117: 744-751. (Pubitemid 29265033)
14. Ghazi NG, Kirk T, Allam S, &, Yan G, (2009): Quantification of error in optical coherence tomography central macular thickness measurement in wet age-related macular degeneration. Am J Ophthalmol 148: 90-96.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, &, Guyer DR,; VEGF inhibition Study in Ocular Neovascularisation Clinical Trial Group (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816. (Pubitemid 40051904)
16. Hee MR, (2005): Artifacts in optical coherence tomography topographic maps. Am J Ophthalmol 139: 154-155. (Pubitemid 40094854)
17. Hee MR, Puliafito CA, Wong C, Reichel E, Duker JS, Schuman JS, Swanson EA, &, Fujimoto JG, (1995a): Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol 120: 65-74.
18. Hee MR, Puliafito CA, Wong C, et al., (1995b): Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 113: 1019-1029.
19. Hee MR, Baumal CR, Puliafito CA, et al., (1996): Optical Coherence tomography of age-related macular degeneration and choroidal neovascularisation. Ophthalmology 103: 1260-1270. (Pubitemid 26282510)
20. Huang D, Swanson EA, Lin CP, et al., (1991): Optical coherence tomography. Science 254: 1178-1181. (Pubitemid 21917444)
21. Joeres S, Tsong JW, Updike PG, Collins AT, Dustin L, Walsh AC, Romano PW, &, Sadda SR, (2007): Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 48: 4300-4307. (Pubitemid 351261062)
22. Ko TH, Fujimoto JG, Schuman JS, et al., (2005): Comparison of ultra-high- and standard resolution optical coherence tomography for imaging of macular pathology. Ophthalmology 112: 1922.
23. Krebs I, Haas P, Zeiler F, &, Binder S, (2008): Optical coherence tomography: limits of the retinal mapping program in age-related macular degeneration. Br J Ophthalmol 92: 933-935. (Pubitemid 351969673)
24. Krebs I, Falkner-Radler C, Hagen S, Haas P, Brannath W, Lie S, Ansari-Shahrezaei S, &, Binder S, (2009): Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT. Invest Ophthalmol Vis Sci 50: 995-1000.
25. Krebs I, Hagen S, Brannath W, Haas P, Womastek I, de Salvo G, Ansari-Shahrezaei S, &, Binder S, (2010): Repeatability and reproducibility of retinal thickness measurements by Optical coherence tomography in age-related macular degeneration. Ophthalmology 117: 1577-1584.
26. Lalwani GA, Rosenfeld PJ, Fung AE, et al., (2009): A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: 2 year of the PrONTO study. Am J Ophthalmol 148: 43-58.
27. Larsen M, Wang M, &, Sander B, (2005): Overnight thickness variation in diabetic macular edema. Invest Ophthalmol Vis Sci 46: 2313-2316. (Pubitemid 43119474)
28. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, &, Gaudric A, (2001): Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 119: 1135-1142. (Pubitemid 32729999)
29. Menke MN, Dabov S, Knecht P, &, Sturm V, (2009): Reproducibility of retinal thickness measurements in patients with age-related macular degeneration using 3D Fourier-domain optical coherence tomography (OCT) (Topcon 3D-OCT 1000). Acta Ophthalmol. [Epub ahead of print].
30. Meyer CH, Eter N, &, Holz FG, & SUSTAIN Study Group (2008): Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the sustain trial. Invest Ophthalmol Vis Sci 49: E-Abstract 273.
31. Mitchell P, Korobelnik J-F, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, &, Wolf S, (2010): Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94: 2-13.
32. Nassif N, Cense B, Park B, et al., (2004): In vivo high-resolution video-rated spectral domain optical coherence tomography of the human retina and optic nerve. Opt Express 12: 367-376.
33. Parravano M, Oddone F, Boccassini B, Menchini F, Chiaravalloti A, Schiavone M, &, Varano M, (2010): Reproducibility of macular thickness measurements using Cirrus spectral domain optical coherence tomography in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 51: 4788-4791.
34. Patel PJ, Chen FK, Ikeji F, Xing W, Bunce C, Da Cruz L, &, Tufail A, (2008): Repeatability of Stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 1084-1088.
35. Patel PJ, Chen FK, Ikeji F, Richardson M, Da Cruz L, &, Tuifal A, (2009a): Intrasession repeatability of optical coherence tomography measures in active neovascular age-related macular degeneration. Acta Ophthalmol Scand. [Epub ahead of print].
36. Patel PJ, Chen FK, da Cruz L, &, Tuifal A, (2009b): Segmentation error in stratus optical coherence tomography for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 50: 399-404.
37. Paunescu LA, Schuman JS, Price LL, Stark PC, Beaton S, Ishikawa H, Wollstein G, &, Fujimoto JG, (2004): Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using Stratus OCT. Invest Ophthalmol Vis Sci 45: 1716-1724. (Pubitemid 38868963)
38. Polito A, Del Borello M, Isola M, Zemella N, &, Bandello F, (2005): Repeatability and reproducibility of fast macular thickness mapping with Stratus optical coherence tomography. Arch Ophthalmol 123: 1330-1337. (Pubitemid 41429732)
39. Puliafito CA, Hee MR, Lin CP, et al., (1995): Imaging of macular diseases with optical coherence tomography. Ophthalmology 102: 217-229.
40. Ray R, Stinnett SS, &, Jaffe GJ, (2005): Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol 139: 18-29. (Pubitemid 40094836)
41. Rosenfeldt PJ, Brown DM, Heijer JS, Boyer DS, Kaiser PK, Chung CY, &, Kim RY,; MARINA Study Group. (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
42. Sadda SR, Wu Z, Walsh AC, Richine L, Dougall J, Cortez R, &, LaBree LD, (2006): Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 113: 285-293. (Pubitemid 43170778)
43. Sadda SR, Joeres S, Wu Z, Updike P, Romano P, Collins AT, &, Walsh AC, (2007): Error correction and quantitative subanalysis of optical coherence tomography data using computer-assisted grading. Invest Ophthalmol Vis Sci 48: 839-848. (Pubitemid 351260721)
44. Schmidt-Erfurth UM, Richard G, Augustin A, et al.,; European Society for Retina Specialists' Guidelines Committee (EURETINA) (2007): Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85: 486-494. (Pubitemid 47163109)
45. Witkin AJ, Vuong LN, Srinivasan VJ, et al., (2009): High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology 116: 956-963.
46. Wojtkowski M, Leitgeb R, Kowalczyk A, Bajraszewski T, &, Fercher AF, (2002): In vivo human retinal imaging by Fourier domain optical coherence tomography. J Biomed Opt 7: 457-463.
47. Wojtkowski M, Bajraszewski T, GorczyÅska I, Targowski P, Kowalczyk A, Wasilewski W, &, Radzewicz C, (2004): Optical imaging by spectral optical coherence tomography. Am J Ophthalmol 138: 412-419. (Pubitemid 39208568)
48. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, Enzmann V, &, Wolf S, (2009): Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 50: 3432-3437.